Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis Theme

1-677-124-44227

184 MAIN COLLINS STREET WEST VICTORIA 8007

FOLLOW US ON INSTAGRAM
Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies

The No.1 Research Site For Therapeutic Peptides

Top

Tirzepatide 5mg

INTRODUCING

Tirzepatide 5mg

Tirzepatide, also known as LY3298176, is a synthetic, dual-acting peptide-based drug developed by Eli Lilly and Company. It acts as an agonist for both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Tirzepatide has been studied primarily for its potential in the treatment of type 2 diabetes and obesity, as it can enhance insulin secretion, suppress glucagon release, and decrease food intake, leading to improved glycemic control and weight loss. 

  • Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial 

Juan Pablo Frias1, Michael A Nauck2, Joanna Van3, Mark E Kutner4, Xuewei Cui5, Charles Benson5, Shweta Urva5, Ruth E Gimeno5, Zvonko Milicevic6, Deborah Robins5, Axel Haupt7 

Affiliations expand 

 

  • LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept 

Tamer Coskun1, Shweta Urva2, William C Roell2, Hongchang Qu2, Corina Loghin2, Julie S Moyers2, Libbey S O’Farrell2, Daniel A Briere2, Kyle W Sloop2, Melissa K Thomas2, Valentina  Pirro2, David B Wainscott2, Francis S Willard2, Matthew Abernathy2, LaRonda Morford2, Yu Du2, Charles Benson2, Ruth E Gimeno2, Axel Haupt2, Zvonko Milicevic3 

Affiliations expand 

 

  • Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial 

Bernhard Ludvik1, Francesco Giorgino2, Esteban Jódar3, Juan P Frias4, Laura Fernández Landó5, Katelyn Brown5, Ross Bray5, Ángel Rodríguez6 

Affiliations expand 

  • Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial 

Juan Pablo Frias1, Michael A Nauck2, Joanna Van3, Mark E Kutner4, Xuewei Cui5, Charles Benson5, Shweta Urva5, Ruth E Gimeno5, Zvonko Milicevic6, Deborah Robins5, Axel Haupt7 

Affiliations expand 

 

Peptides are the future of medicine. They are potent, tissue specific and effective at treating a variety of conditions with little to no side effects.

Dean Henry
Function Medicine Coach and Health Optimiser

Peptides are the next frontier in biohacking and performance enhancement. They can boost muscle growth, accelerate fat loss, improve sleep, increase energy and focus, and promote overall health and longevity.

Ben Greenfield
Biohacker and Health Expert

Peptides are tiny chains of amino acids that have powerful effects on the brain and body. They can improve memory, focus, and mood, and have anti-anxiety and anti-depressant effects.

Dr. Andrew Huberman, PhD
Professor of Neurobiology at Stanford University